ANKDD1A and central nervous system cancer: ANKDD1A has been described as a functional tumor suppressor with germline variants predicting poor patient outcomes in low grade glioma [40], and is frequently methylated in glioblastoma multiforme [41] and in clinically non-functioning pituitary adenomas [42].